J.Molner AS (OTSE:MOLNR) DeferredTaxAndRevenue: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OTSE:MOLNR J.Molner AS OTSE:MOLNR
40 GF Score
Price €18.90
GF Value €19.62
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is J.Molner AS DeferredTaxAndRevenue?

J.Molner AS OTSE:MOLNR 40 DeferredTaxAndRevenue is €0.00 Mil as of Dec. 2025. GuruFocus rates OTSE:MOLNR with a GF Score™ of 40/100 and a GF Value™ of €19.62 (Fairly Valued). The stock has 7 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

J.Molner AS's current deferred tax and revenue for the quarter that ended in Dec. 2025 was €0.00 Mil.

J.Molner AS DeferredTaxAndRevenue Related Terms

J.Molner AS DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for J.Molner AS's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

J.Molner AS DeferredTaxAndRevenue Chart

J.Molner AS Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
0.00 0.00 0.00 0.00 0.00

J.Molner AS Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
OTSE:MOLNR
40GF Score
J.Molner AS OTSE:MOLNR
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of €0.00 Mil mean?
J.Molner AS (OTSE:MOLNR) has a DeferredTaxAndRevenue of €0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on J.Molner AS.
Is J.Molner AS's DeferredTaxAndRevenue too high?
J.Molner AS's current DeferredTaxAndRevenue is €0.00 Mil. Overall, J.Molner AS has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's DeferredTaxAndRevenue compare to ZTS and UTHR?
J.Molner AS's DeferredTaxAndRevenue of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Drug Manufacturers company?
A good DeferredTaxAndRevenue depends on the Drug Manufacturers industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on J.Molner AS. J.Molner AS's current DeferredTaxAndRevenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.62, compared to a current price of €18.90 — trading 3.7% below its estimated fair value. The current DeferredTaxAndRevenue is €0.00 Mil. J.Molner AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current DeferredTaxAndRevenue is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?

Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued. The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.62. GuruFocus considers J.Molner AS to be Fairly Valued.

Key valuation signals for OTSE:MOLNR:

  • DeferredTaxAndRevenue: €0.00 Mil
  • GF Value™: €19.62 vs. price of €18.90 (3.7% below fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

J.Molner AS Business Description

Address Akadeemia tee 21/5, Harju maakond, Tallinn, EST, 12618
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score

Get the complete analysis for OTSE:MOLNR

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.90
Price
€19.62
GF Value